|Host||Purified From Concentrated Hybridoma Tissue Culture Supernatant.|
|Application Note||,Functional Application, Inhibition of human BAFF binding,IP(1:200)|
|Other Names||BLyS; TALL-1; CD257; B Cell Activating Factor; TNFSF13B|
|Target/Specificity||Recognizes human BAFF.|
|Format||Liquid. In PBS containing 10% glycerol and 0.02% sodium azide.|
|Reconstitution & Storage||Stable for at least 1 year after receipt when stored at -20°C.|
|Precautions||Functional BAFF (human) Antibody, mAb (blocking) is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
BAFF is a master regulator of peripheral B cell survival, and together with IL-6, promotes Ig class-switching and plasma cell differentiation. BAFF co-stimulates activated T cells. Increased levels of soluble BAFF have been detected in the serum of patients with various autoimmune diseases, such as Sjögren’s syndrome, rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus (SLE). Furthermore, BAFF is found in inflammatory sites in which there is lymphoid neogenesis. BAFF levels are elevated in patients with multiple myeloma and B cell chronic lymphoid leukemia (B-CCL).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.